Just got this back from Leo after I sent him a link to the article PP posted.
They did a much larger trial. Their patients were dosed by infusion multiple times a week for a number of hours. Obviously a huge disadvantage to our brilacidin rinse. We are not concerned. You can't disregard their placebo arm SOM percentage which was slightly lower than ours. In addition they reported "in the overall incidence of SOM through 60 Gy of radiation" We reported "cumulative radiation dose criteria of at least 55 Gy—the minimum treatment threshold for inclusion in the efficacy population." So we made it more challenging for ourselves by using the lower number of 55GY.
We had multiple meetings in San Francisco and believe pharmas view us as the leaders in the race for a drug to prevent SOM.
Market Data 
Markets 
AI
